戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  dead cells was saturated by the addition of pentosan polysulfate.
2 g, subcutaneously, in olive oil)/5% glucose, pentosan polysulfate (10 mg/kg, subcutaneously in 5% glu
3 scrapie protease-resistant PrP accumulation, pentosan polysulfate and a porphyrin compound, indium (I
4 ytic digestion of protamine, and polyanions (pentosan polysulfate and heparin) based on the strong bi
5                    Heparin, dextran sulfate, pentosan polysulfate, and a sulfated synthetic copolymer
6 , unlabeled heparan sulfate, and heparin and pentosan polysulfate, but not in the presence of chondro
7                    Here we show that calcium pentosan polysulfate (CaPPS), a chemically sulfated xyla
8                             The detection of pentosan polysulfate concentrations in an undiluted urin
9 nal nitric-oxide synthase mRNA levels in the pentosan polysulfate/CsA-treated group.
10 bulo-interstitial lesions (44%) was found in pentosan polysulfate/CsA-treated rats.
11 lar volume was found in CsA rats, but not in pentosan polysulfate/CsA-treated rats.
12 lfate = dermatan sulfate = dextran sulfate > pentosan polysulfate, implicating the importance of the
13  spectropolarimetry measurements showed that pentosan polysulfate induced a conformational change in
14 vCJD) have been treated with intraventicular pentosan polysulfate (iPPS) and extended survival has be
15     In this study, we examined the effect of pentosan polysulfate on the development of CsA nephropat
16 r U-73122, by blocking the IP3 receptor with pentosan polysulfate or heparin, and by buffering intrac
17 taneously in 5% glucose) plus CsA, olive oil/pentosan polysulfate, or olive oil/5% glucose for 30 day
18 om normal mice was used to determine whether pentosan polysulfate (PPS) inhibited proliferation and a
19                                              Pentosan polysulfate (PPS) is a glycan derivative that i
20 age models (MLLM) diagnose and differentiate Pentosan Polysulfate (PPS) Maculopathy from other phenot
21 ing evidence of a direct association between pentosan polysulfate (PPS) therapy and the development o
22 of the glycosaminoglycan (GAG)-like molecule pentosan polysulfate (PPS) to alleviate virus-induced ar
23                          We investigated how pentosan polysulfate (PPS), a polyanion with antiprion a
24 by using an established anti-prion compound, pentosan polysulfate (PPS).
25 in patients with maculopathy associated with pentosan polysulfate (PPS).
26  23-106) and fragments thereof when bound to pentosan polysulfate (PPS).
27 he sequence of antithrombin III (n = 9); and pentosan polysulfate (PPS; n = 7).
28                Both elevated temperature and pentosan polysulfate promoted interspecies PrP conversio
29                                              Pentosan polysulfate reduced structural renal lesions in
30  sodium maculopathy (PPSM) in patients using pentosan polysulfate sodium (PPS) and model the dose-res
31 e the spectrum of clinical manifestations of pentosan polysulfate sodium (PPS) maculopathy observed a
32 ypothesized to be associated with the use of pentosan polysulfate sodium (PPS).
33 o determine the pooled relative risk (RR) of pentosan polysulfate sodium maculopathy (PPSM) in patien
34                                              Pentosan polysulfate sodium maculopathy is an acquired,
35  Stepwise dosing (5 to 60 mug/m(2)/day) plus pentosan polysulfate SP54 (n = 3) resulted in no treatme
36                    We showed previously that pentosan polysulfate (SP54) prevented the development of
37                          Heparan sulfate and pentosan polysulfate stimulated PrP-res formation.
38                                              Pentosan polysulfate treatment did not prevent the CsA-i
39                    Adverse event reports for pentosan polysulfate were selected and compared with adv